Baxter Shares Tank As 2026 Profit Guidance Falls Below Expectations

Core Insights - Baxter reported a fourth-quarter adjusted EPS of 44 cents, which was below management guidance of 52-57 cents and Wall Street estimate of 54 cents, primarily due to an unfavorable product mix [1] - The company achieved sales of $2.974 billion, representing an 8% year-over-year increase on a reported basis and a 3% increase on an operational basis, surpassing the consensus estimate of $2.824 billion [1] Sales Performance - Medical Products & Therapies segment sales were approximately $1.39 billion, increasing by 6% on a reported basis and 4% on an operational basis, driven by higher sales in the Infusion Therapies & Technologies division and strong global demand for Advanced Surgery products [3] - Healthcare Systems & Technologies segment sales reached $827 million, up 5% on a reported basis and 4% on an operational basis, reflecting demand for Care & Connectivity Solutions products and growth in the Front Line Care division [4] - Pharmaceutical sales totaled approximately $668 million, an increase of 4% on a reported basis and 2% on an operational basis, with continued strength in Drug Compounding partially offset by reduced sales in Injectables & Anesthesia [4] Management Commentary - The CEO emphasized that while sales growth was achieved across all segments, the fourth-quarter results did not meet expectations, highlighting the need for continuous improvement and the introduction of a new operating model aimed at simplifying the organization and enhancing performance [5] Future Guidance - Baxter expects fiscal 2026 adjusted earnings to be between $1.85-$2.05 per share, compared to the consensus of $2.25, with an adjusted operating margin projected between 13%-14% [6] - The company forecasts 2026 sales to be between $11.24 billion and $11.36 billion, slightly below the consensus of $11.31 billion, with expected sales growth flat to an increase of 1% [6] Stock Performance - Baxter shares were down 15.6% at $18.79 at the time of publication, trading near its 52-week low of $17.4 [7]